Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET
Company Participants
Jenny Kobin - IR
George Lasezkay - CEO
Victor Chong - Chief Medical Officer
Charlie Deignan - CFO
Conference Call Participants
Annabel Samimy - Stifel
Andreas Argyrides - Oppenheimer
Debanjana Chatterjee - JonesTrading
Operator
Greetings, and welcome to the Clearside Biomedical Third Quarter 2024 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. [Operator Instructions] Please note, this conference is being recorded.
I will now turn the conference over to your host, Jenny Kobin, Investor Relations. Ma'am, you may begin.
Jenny Kobin
Good afternoon, everyone, and thank you for joining us on the call today.
Before we begin, I would like to remind you that during today's call, we will be making certain forward-looking statements. Various remarks that we make during this call about the company's future expectations, plans and prospects constitute forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our annual report on Form 10-K for the year ended December 31, 2023, that was filed on March 2024, and our quarterly report on Form 10-Q for the quarter ended September 30, 2024, filed today, and our other SEC filings available on our website.
In addition, any forward-looking statements represent our views as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so even if our views change.
On today's call, we have George Lasezkay, our Chief Executive Officer; Dr. Victor Chong, our Chief Medical Officer; and Charlie Deignan, our Chief Financial Officer. After our formal remarks, we will open the call for your questions.
I would now like to turn the call over to George.
George Lasezkay
Thank you, Jenny, and good afternoon, everyone. We continue to make outstanding progress advancing our differentiated suprachoroidal delivery pipeline. Last month we reported the positive results from our ODYSSEY Phase 2b clinical trial in patients with wet AMD. These data strongly support the potential efficacy, safety and versatility of CLS-AX to treat this chronic disease.